|[March 20, 2017]
Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada
Ferring Pharmaceuticals and CD Investments (CDI) announced today that
they have signed an agreement granting Ferring exclusive European
marketing rights to CDI's VSL#3®. This agreement extends
Ferring's existing rights to market the product in the UK, Italy and
VSL#3® is a food supplement, containing 450 billion live
bacteria in eight different strains per sachet, which colonizes the gut
and benefits from a unique formulation. Research has confirmed that
probiotic bacteria modulate mucosal and systemic immune activity and
epithelial function(1), with favorable impact on gut health.
"VSL#3® expands our existing gastroenterology portfolio and
is a key part of our regional pharmabiotic strategy," said Gilles
Pluntz, Senior Vice President Europe-Canada, Ferring Pharmaceuticals.
"This agreement complements our innovative research in the area of the
human microbiome, and reflects Ferring's commitment to enhancing the
quality of life of patients with a broad range of bowel conditions."
"We are delighted to expand our collaboration with Ferring, and build on
the current success of VSL#3® in the UK, Italy and Canada,"
said Luca Guarna, President of the Board of Directors of CD Investments.
"With the company's long heritage in gastroenterology and commitment to
patients, Ferring will help make VSL#3® a successful brand
across Europe and Canada."
- Ends -
VSL#3® is a combination of live lactic acid bacteria that
have been cultivated, freeze-dried and mixed in a very high
concentration (hundreds of billions per gram). It contains eight
different strains of bacteria whch have been selected, cultivated in
and mixed in proportions in order to optimize the functionality of the
product. To learn more about VSL#3® please visit www.vsl3pharma.com.
About the Microbiome
To understand the role that probiotics may have in influencing health,
it is important to have an appreciation of the roles of the normal
intestinal microbiome. The human body is host to trillions of microbes,
bacteria, virus and fungi. This vast and complex microbial community is
known as the microbiota. Each of the different microorganisms in the
microbiota has its own unique set of genes. The collective name for all
of the genes in the microbiota is the microbiome. Rapidly evolving
science has uncovered a central role of the microbiome in human health
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a private
research-driven, specialty biopharmaceutical group active in global
markets. The company identifies, develops and markets innovative
products in the areas of reproductive health, urology, gastroenterology,
endocrinology and orthopaedics. Ferring has its own operating
subsidiaries in nearly 60 countries and markets its products in 110
countries. To learn more about Ferring or its products please visit www.ferring.com.
About CD Investments (VSL Pharmaceuticals, Inc.)
CD Investments is a holding company with three subsidiaries worldwide,
CD Investments for the European market, CD Pharma India for the
Asia-Pacific market and VSL Pharmaceuticals for the North, Central and
CD Investments is focused on the development of products based on the
technological platform of probiotic bacteria (lactic acid bacteria and
bifidobacteria) for use as food supplement/nutraceuticals in various
physiological/pathological conditions. The company has a number of
patents which cover many aspects of the therapeutic and nutraceutical
use of probiotics and of enzymes derived from probiotic bacteria, in
different pathophysiological conditions, both as dietetic preparations,
and food supplements, or as pharmaceutical products. To learn more about
CD Investment please visit www.vsl3pharma.com.
(1) Fedorak R., J Clin Gastroenterol - Volume 42, Supp. 3,
Part 1, September 2008 S111
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005512/en/
[ Back To TMCnet.com's Homepage ]